Coalition to Cure Calpain 3 (C3) has launched the first and only limb-girdle muscular dystrophy type 2A (LGMD2A/R1) patient registry. In celebration of ten years of progress in our mission to fund research for a cure and raise global awareness,
Promising study identifies compound that improves muscle in LGMD2A/R1 mice
A new publication from Dr. Melissa Spencer’s laboratory at the University of California Los Angeles identifies a compound that mimics the effects of exercise in a mouse model of limb girdle muscular dystrophy type 2A (LGMD2A/R1). These studies may point
C3 is connecting patients with one another!
Coalition to Cure Calpain 3 is a vital hub connecting patients with limb-girdle muscular dystrophy type 2A (LGMD2A/R1) with one another. In celebration of ten years of progress in our mission to fund research for a cure and raise global
C3 is Building Scientific Leadership
Coalition to Cure Calpain 3 is leading the charge to assemble the best scientific minds to solve limb-girdle muscular dystrophy type 2A (LGMD2A/R1). In celebration of ten years of progress in our mission to fund research for a cure and build
C3 is Putting LGMD on the Map!
Coalition to Cure Calpain 3 is putting limb-girdle muscular dystrophy type 2A (LGMD2A/R1) on the map! In celebration of ten years of progress in our mission to fund research for a cure and raise global awareness, C3 is proud to
C3 Celebrates a Decade of Achievement
Coalition to Cure Calpain 3 (C3) has come a long way in ten years in driving science and awareness to treat limb girdle muscular dystrophy, type 2A (known as LGMD2A/R1, LGMD R1 Calpain 3 related, or calpainopathy). In celebration of ten